THALES
23.1.2024 09:01:30 CET | Business Wire | Press release
Thales, the leading global technology and security provider, today announced the launch of its PQC Starter Kit in collaboration with Quantinuum (https://www.quantinuum.com). This first-of-its-kind offering helps enterprises prepare for Post-Quantum Cryptography (PQC). The kit provides a trusted environment for businesses to test quantum-hardened PQC-ready encryption keys and understand the implications that quantum computing will have on the security of their infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123494135/en/
©Thales
While 73% of organizations recognize quantum computing poses a threat to traditional cryptography, 61% have yet to define a strategy for a post-quantum world1. Post Quantum Cryptography helps mitigate this threat. As a result, organizations around the world must test their ecosystem applications, data, and devices currently relying upon traditional cryptography to ensure minimal disruption when quantum-safe protocols become mandatory.
Todd Moore, Global Head of Data Security Products at Thales commented: “Thales is excited to offer a new solution to its customers to help them prepare for the implementation of Post-Quantum Cryptography. We understand the enormous challenges and complexities behind this upcoming disruption in cryptography and want to support customers as they transition to these new algorithms.. For organizations unsure of navigating this transition, we highly recommend testing current applications, data, and devices that use cryptographic protection as soon as possible to ensure a smooth shift to PQC. Although quantum computing may seem like a future-looking risk, with hackers using Harvest Now, Decrypt Later tactics, post-quantum resilience should be on every organization’s radar today.”
"Hardening encryption keys is critical for the post-quantum era, and Quantum Origin is a unique technology that provides verifiable quantum randomness to maximize encryption key strength. The combination of Quantum Origin and the Thales HSM is a strong solution for IT teams to help them with their PQC transition. We look forward to working with Thales to help smooth the shift to PQC,” added Duncan Jones, Head of Cybersecurity at Quantinuum.
The PQC Starter Kit will allow organizations to test within a trusted lab environment. Using the current NIST proposed algorithms that are built into the system, customers can test various security use cases including PKI, code-signing, TLS, and IoT, and observe the impact of implementing PQC technology in these simulated test-lab scenarios, all without impacting operational processes in real-world production environments. Organizations will also be able to identify potential weaknesses in their encryption deployment and apply changes to their IT infrastructure to protect themselves.
The first available PQC Starter Kit option incorporates Luna HSMs and Quantinuum’s quantum random number generation (QRNG) technology through which customers can ensure their keys are securely generated and stored while testing the PQC algorithms. The kit offers a choice of Luna HSMs (i.e. appliance or PCIe card) and Quantinuum’s Quantum Origin - the world’s only source of verified quantum entropy. A PQC Starter Kit for network encryption using Thales High Speed Encryptors (HSE) will be available next.
Learn more about the PQC Starter Kit in the customer case study here.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.
PLEASE VISIT
Thales Group
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
1 Cybersecurity Weaknesses in Data in Motion - White Paper (thalesgroup.com)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123494135/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
